BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy confers a survival benefit on patients with esophageal cancer. However, nCRT might be less meaningful for poor responders. Thus, being able to predict responses would help ensure the selection of optimal therapy. METHODS: We reviewed data from 123 patients with esophageal squamous cell carcinoma (ESCC) who underwent nCRT that comprised concurrent radiation (40 Gy) and chemotherapy followed by esophagectomy. We assessed associations between clinical and blood data obtained before starting nCRT and the pathologic response. RESULTS: We compared good (Japan Esophageal Society response evaluation criteria grades 3/2; n = 89, 72.4%) and poor (grades 1/0; n = 34, 27.6%) responders. Performance status (p = 0.02), hemoglobin level (p = 0.005), and platelet counts (p = 0.03) were statistically significant pretherapeutic factors for a response to nCRT. Multivariable analysis subsequently selected the hemoglobin level (odds ratio 1.52; 95% confidence interval 1.08-2.15; p = 0.02) as the sole independent predictor. Receiver operating characteristic curves showed that the optimal cutoff for pretherapeutic hemoglobin was 13 g/dl for predicting a response. We found that 48.8 and 17.1% of patients with hemoglobin level ≤13 and >13 g/dl, respectively, were poor responders (p = 0.0002), with 5-year overall survival rates of 40.9 and 58.9%, respectively (p = 0.048). CONCLUSIONS: Pretherapeutic hemoglobin levels can influence responses and survival after nCRT for ESCC. Thus, hemoglobin levels can serve as a useful marker for tailoring optimal therapies for individual patients with advanced ESCC.
BACKGROUND: Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy confers a survival benefit on patients with esophageal cancer. However, nCRT might be less meaningful for poor responders. Thus, being able to predict responses would help ensure the selection of optimal therapy. METHODS: We reviewed data from 123 patients with esophageal squamous cell carcinoma (ESCC) who underwent nCRT that comprised concurrent radiation (40 Gy) and chemotherapy followed by esophagectomy. We assessed associations between clinical and blood data obtained before starting nCRT and the pathologic response. RESULTS: We compared good (Japan Esophageal Society response evaluation criteria grades 3/2; n = 89, 72.4%) and poor (grades 1/0; n = 34, 27.6%) responders. Performance status (p = 0.02), hemoglobin level (p = 0.005), and platelet counts (p = 0.03) were statistically significant pretherapeutic factors for a response to nCRT. Multivariable analysis subsequently selected the hemoglobin level (odds ratio 1.52; 95% confidence interval 1.08-2.15; p = 0.02) as the sole independent predictor. Receiver operating characteristic curves showed that the optimal cutoff for pretherapeutic hemoglobin was 13 g/dl for predicting a response. We found that 48.8 and 17.1% of patients with hemoglobin level ≤13 and >13 g/dl, respectively, were poor responders (p = 0.0002), with 5-year overall survival rates of 40.9 and 58.9%, respectively (p = 0.048). CONCLUSIONS: Pretherapeutic hemoglobin levels can influence responses and survival after nCRT for ESCC. Thus, hemoglobin levels can serve as a useful marker for tailoring optimal therapies for individual patients with advanced ESCC.
Authors: George W Dittrick; Jill M Weber; Ravi Shridhar; Sarah Hoffe; Marcovalerio Melis; Khaldoun Almhanna; James Barthel; James McLoughlin; Richard C Karl; Kenneth L Meredith Journal: Ann Surg Oncol Date: 2011-11-02 Impact factor: 5.344
Authors: Jin Hwi Kim; Joon Mo Lee; Ki Sung Ryu; Yong Seok Lee; Yong Gyu Park; Soo Young Hur; Keun Ho Lee; Sung Ha Lee Journal: Oncologist Date: 2011-06-24
Authors: B L D M Brücher; H J Stein; F Zimmermann; M Werner; M Sarbia; R Busch; H J Dittler; M Molls; U Fink; J R Siewert Journal: Eur J Surg Oncol Date: 2004-11 Impact factor: 4.424
Authors: S Zenda; S Hironaka; N Boku; K Yamazaki; H Yasui; A Fukutomi; T Yoshino; Y Onozawa; T Nishimura Journal: Dis Esophagus Date: 2008 Impact factor: 3.429
Authors: Stephen G Maher; Charles M Gillham; Shane P Duggan; Paul C Smyth; Nicola Miller; Cian Muldoon; Kenneth J O'Byrne; Orla M Sheils; Donal Hollywood; John V Reynolds Journal: Ann Surg Date: 2009-11 Impact factor: 12.969
Authors: Christian Daniel Fankhauser; Sophia Sander; Lisa Roth; Oliver Gross; Daniel Eberli; Tullio Sulser; Burkhardt Seifert; Joerg Beyer; Thomas Hermanns Journal: Br J Cancer Date: 2018-02-27 Impact factor: 7.640